In this issue:
- Second ISS revision for OS in MM
- CTCs for staging newly diagnosed transplanteligible MM
- Impact of autologous HCT on disease burden by NGS in quadruplet-treated MM
- Paraskeletal and EMPs at MM diagnosis and first relapse
- Neutralising antibody response after SARS-COV-2 vaccination in myeloma
- Teclistamab for relapsed/ refractory MM
- Cost effectiveness of frontline daratumumab in transplanteligible newly diagnosed MM
- Early mortality predictors in MM
- Isatuximab ±Kd in relapsed MM with high-risk cytogenetics
- VTE risk with adding daratumumab to RVd in newly diagnosed MM
Download PDF